汉防己甲素片联合注射用重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白对类风湿性关节炎患者炎症指标、免疫功能及骨代谢指标的影响  

Effects of tetrandrine tablets combined with recombinant human type Ⅱ tumor necrosis factor receptor-antibody fusion protein for injection on inflammatory indexes, immune function and bone metabolism indexes in patients with rheumatoid arthritis

作　　者：李晓华 曾静娟 LI Xiaohua;ZENG Jingjuan(Rheumatology Diagnosis and Treatment Center,Xi'an People's Hospital/Xi'an Fourth Hospital,Xi'an 710004,China)

机构地区：[1]西安市人民医院/西安市第四医院风湿病诊治中心,陕西西安710004

出　　处：《临床医学研究与实践》2025年第6期69-72,共4页Clinical Research and Practice

摘　　要：目的 探讨汉防己甲素片联合注射用重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白对类风湿性关节炎(RA)患者炎症指标、免疫功能及骨代谢指标的影响。方法 选取2022年5月至2023年5月我院收治的108例RA患者为研究对象,将其随机分为对照组(54例,注射用重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白)和研究组(54例,汉防己甲素片联合注射用重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白)。比较两组的临床效果。结果 研究组的治疗总有效率高于对照组(P<0.05)。治疗后,研究组的晨僵时间短于对照组,视觉模拟评分法(VAS)评分低于对照组(P<0.05)。治疗后,研究组的肿瘤坏死因子-α(TNF-α)、白细胞介素-10(IL-10)及白细胞介素-17(IL-17)水平显著低于对照组(P<0.05)。治疗后,研究组的CD3^(+)、CD4^(+)及CD4^(+)/CD8^(+)显著低于对照组(P<0.05)。治疗后,研究组的骨钙素(BGP)及25-羟维生素D[25(OH)D]水平显著高于对照组(P<0.05)。两组的不良反应总发生率无显著差异(P>0.05)。结论 汉防己甲素片联合注射用重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白治疗RA的效果显著,可缩短患者的晨僵时间,降低疼痛程度及炎症反应,改善免疫功能及骨代谢情况。Objective To investigate the effects of tetrandrine tablets combined with recombinant human typeⅡtumor necrosis factor receptor-antibody fusion protein on inflammatory indexes,immune function and bone metabolism indexes in patients with rheumatoid arthritis(RA).Methods A total of 108 RA patients admitted in our hospital from May 2022 to May 2023 were selected as study objects,and the patients were randomly divided into control group(54 cases,recombinant human typeⅡtumor necrosis factor receptor-antibody fusion protein for injection)and study group(54 cases,tetrandrine tablets combined with recombinant human typeⅡtumor necrosis factor receptor-antibody fusion protein for injection).The clinical effects of the two groups were compared.Results The total effective rate of treatment in the study group was higher than that in the control group(P<0.05).After treatment,the morning stiffness time of the study group was shorter than that of the control group,and the Visual Analogue Scale(VAS)score was lower than that of the control group(P<0.05).After treatment,the levels of tumor necrosis factor-α(TNF-α),interleukin-10(IL-10)and interleukin-17(IL-17)in the study group were significantly lower than those in the control group(P<0.05).After treatment,the CD3^(+),CD4^(+)and CD4^(+)/CD8^(+)in the study group were significantly lower than those in the control group(P<0.05).After treatment,the levels of boneγ-carboxyglutamic-acid-containing protein(BGP)and 25-hydroxy-vitamin D[25(OH)D]in the study group were significantly higher than those in the control group(P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups (P>0.05). Conclusion Tetrandrine tablets combined with recombinant human type Ⅱ tumor necrosis factor receptor-antibody fusion protein for injection has a significant effect in the treatment of RA, which can shorten the morning stiffness time of patients, reduce the degree of pain and inflammatory response, and improve immune function and bone metabolis

关 键 词：汉防己甲素片 注射用重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白 类风湿性关节炎 

分 类 号：R593.22[医药卫生—内科学]